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Major considerations in the provision of healthcare are availability, affordability,
accessibility, and appropriateness, especially in the setting of heart failure where
disease burden is growing, developments have been rapid and newer biomarkers, di-
agnostic and imaging techniques, monitoring systems, devices, procedures, and
drugs have all been developed in a relatively short period of time. Many monitoring
and diagnostic systems have been developed but the disproportionate cost of con-
ducting trials of their effectiveness has limited their uptake. There are added com-
plexities, in that the utilization of doctors for the supervision of the monitoring
results may be optimal in one setting and not in another because of differences in
the characteristics of organization of healthcare provision, making even interpreta-
tion of the trials we have had, still difﬁcult to interpret. New technologies are con-
tinuously changing the approach to healthcare and will reshape the structure of the
healthcare systems in the future. Mobile technologies can empower patients and
carers by giving them more control over their health and social care needs and re-
ducing their dependence on healthcare professionals for monitoring their health, but
a signiﬁcant problem is the integration of the multitude of monitored parameters
with clinical data and the recognition of intervention thresholds. Digital technology
can help, but we need to prove its cost/efﬁcacy and how it will be paid for.
Governments in many European countries and worldwide are trying to establish
frameworks that promote the convergence of standards and regulations for telemed-
icine solutions and yet simultaneously health authorities are closely scrutinizing
healthcare spending, with the objective of reducing and optimizing expenditure in
the provision of health services. There are multiple factors to be considered for the
reimbursement models associated with the implementation of physiological monitor-
ing yet it remains a challenge in cash-strapped health systems.
Introduction
Access to healthcare is central to wellbeing, life expec-
tancy, and social protection. However, there is not an
agreed definition or standard approach to its availability
across the world and even across the more developed EU
systems. Key dimensions of access to healthcare are avail-
ability, affordability, accessibility, and appropriateness.
These concepts are crucial to understand how the
healthcare system can approve and pay for new monitoring
systems for physiological parameters and drug efficacy in
chronic disease states. This is especially relevant in heart
failure (HF) where disease burden is growing, develop-
ments have been rapid and newer biomarkers, diagnostic
and imaging1 techniques, monitoring systems, devices,
procedures, and drugs2–4 have all been developed in a rela-
tively short period of time. Many monitoring and diagnostic
systems, for example, have been proven to be efficacious
in one healthcare system5 or setting,6–9 but not in others,10
where the background risk,11 the level12 and type of pa-
tient care,13 and follow-up arrangements may be quite var-
ied,14 carrying with it a differing ability to respond to the
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new information monitoring can provide. Some are highly
specific to the settings in which they potentially add clini-
cal value15–17 and expecting large-scale outcome trials for
every aspect of improved clinical care may be an unrealis-
tic expectation. Even the type of patient18 that eventually
gets into trials may, for many reasons, be different from
real-world HF patients.19,20 The trials themselves need to
be monitored21–23 adding cost and complexity24 and poten-
tially acting as a brake on health system care delivery im-
provement as a result. Simple aspects of healthcare25–27
cannot be tested in large-scale trials, we simply cannot af-
ford so to do.
Access to healthcare is integral part of the European
Pillar of Social Rights. However, the type of quality, effec-
tiveness of healthcare vary greatly amongst European
Countries. This is dependent of how the health system de-
veloped prior to the European integration in the individual
Countries and the funds available/allocated in each
Country for healthcare. Low effectiveness of healthcare
has a negative impact on access to new technologies.
However, the use of ineffective technologies leads to a
waste of healthcare resources.28 On the other hand, inex-
pensive treatments may be very difficult to introduce be-
cause of the disproportionate cost of conducting trials of
their effectiveness.29,30
Inappropriate monitoring or ineffective technologies
may cause an overuse of procedures rather than at unpro-
blematic accessibility. Also, the utilization of human
resources is an integral part of the provision of new tech-
nologies and depends on the characteristics and organiza-
tion of the specific healthcare system. The utilization of
doctors for the supervision of the monitoring results may
be optimal in one setting and not in another because of dif-
ferences in the characteristics of organization of health-
care provision, making even overviews of multiple trials
hard to interpret.31,32
New technologies are continuously changing the ap-
proach to healthcare and will reshape the structure of the
healthcare systems in the future. Some systems such as the
UK’s NHS are more responsive to these innovations while
others are slower in embracing them, although in each the
cost-benefit relationship may be very different.33–35
Mobile technologies can empower patients and carers by
giving them more control over their healthcare and social
care needs and reducing their dependence on healthcare
professionals (HCPs) for monitoring their health.36 They
can improve not only self-management through education,
remotemonitoring, and treatment adherence but also sup-
port development of online healthcare provision. The main
problem is the integration of the multitude of monitored
parameters with clinical data and the recognition of inter-
vention thresholds.
Digital technology can connect patients and providers,
leading to a more convenient and tailored service.
However, this service has to prove its cost/efficacy before
being implemented and paid for.37
Remote monitoring uses technology to monitor changes
in patients’ health status outside of the clinical settings.
These systems have initially been developed by conveying
information through fixed-line technology now they use
mobile/Wifi/Bluetooth infrastructures. They allow HF
patients to use a device to perform a measurement of a
physiological parameter38 and to send the data to a health-
care professional or to a system that uses artificial intelli-
gence to trigger signals when needed. The use of
integrated physiological monitoring should be prompted by
an HCP. However, digital technology has increased the po-
tential for remote monitoring and, with the advent of apps
and wearables, patients are increasingly bringing the inno-
vation to HCPs.
Recent advances in the development of bio-sensing
wearables are extending their capability to move beyond
simply tracking activity. New technologies allow a continu-
ous monitoring of a broad range of physiological parame-
ters. Development in bio-sensing wearables allow
automated monitoring and detecting real-time changes in
patients with HF. Data gathered from physiological moni-
toring can be used to update medical history and real-time
information to support early detection in worsening of
health status.39
Despite the general excitement for the new technologies
and their supposed potentials, if they have to be integrated
in the healthcare provisions they will have, individually of
globally when integrated in a detection system, to prove
their efficacy in reducing hospitalizations and deaths and
their cost/effectiveness.
Governments in many European countries and worldwide
are trying to establish frameworks that promote the con-
vergence of standards and regulations for telemedicine sol-
utions. The Global Harmonization Task Force has been
commenced by a group of countries (the EU, USA, Canada,
Japan, and Australia), with the objective of streamlining
and harmonizing all regulatory requirements regarding
medical technologies. This process may enable a better
economic assessment of the cost/efficacy of the technolo-
gies and, therefore, enable decisions on reimbursements.
Different forms of delivery and use of remote monitoring
solutions for patients with HF can define the supply and de-
mand structure for the provision of services. The cost of
providing remote physiological monitoring solutions and
services can be managed by a service model operated by
service providers, and a technology platform model oper-
ated by medical personnel. Factors influencing invest-
ments in monitoring physiological parameters in HF
patients depend on the access to mobile technology, on the
safety of information technology security, and on the need
for chronic care. Healthcare systems are mainly focused on
hospital-centric care models that absorb more than 90% of
the cost of care for HF patients and are not usually well
equipped to meet the challenges of physiological
monitoring.
Health authorities are closely scrutinizing healthcare
spending, with the objective of reducing and optimizing
expenditure in the provision of health services, and of
replacing older established therapies with newer perhaps
less risk-prone therapies.40 Because of the constant in-
crease in demands for health services driven by demo-
graphics and epidemiology, and lower relative funding for
health systems, diffusion and access to physiological moni-
toring services will become a major concern in the short
term.
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There are several factors to be considered for the reim-
bursement models associated with the implementation
of physiological monitoring services across the EU.
The escalating costs associated with healthcare provision
(infrastructure and operational expenditure) and the dy-
namics of the workforce in the medical field play a major
role in defining the costs. The needs of service improve-
ment require we look regularly at the effectiveness of rou-
tine practice41,42 and ways to incrementally improve
outcomes.43–45
The availability of additional financial resources to be al-
located to healthcare is also problematic in some countries
and this has an impact on the decision making about the
reimbursability.
However, healthcare systems continue to struggle with
unsustainable conditions due to demographic dynamics in
the EU and elsewhere, the decreasing share of the active
population, and the increasing need for treatment for
chronic diseases.
The financing of healthcare provisions for physiological
monitoring will require complementing healthcare funds
with private expenditure (e.g. out-of-pocket payments
and patient co-payments). However, this may prove ex-
tremely difficult, as most of the healthcare systems have
traditionally been mainly funded by public sources. Of
course, should individual physiological monitoring prove to
be cost-effective, they can be immediately be embraced
and reimbursed by the healthcare system providing that
they will lead to savings on hospital expenditure in the long
term.
It is generally stated that the adoption of physiological
monitoring increases benefits, reduces costs (consultation
costs, travel costs, and time spend) and increases patient
survival and quality of life. However, more scientific evi-
dence is needed to demonstrate the cost/efficiency of
physiological monitoring and large-scale trials are needed
to demonstrate the impact of a wider deployment.
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